Safety and Effectiveness of PEG-Intron in HIV-Infected Patients

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00005012
First received: March 29, 2000
Last updated: June 23, 2005
Last verified: August 2000
  Purpose

The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).


Condition Intervention Phase
HIV Infections
Drug: Peginterferon alfa-2b
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Primary Purpose: Treatment
Official Title: Antiviral Activity and Tolerability of PEG-Intron in HIV-Infected Subjects Failing HAART

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 250
Study Start Date: March 2000
Estimated Study Completion Date: September 2000
Detailed Description:

At entry, patients undergo HIV genotypic/phenotypic analysis. Patients continue their current antiretroviral regimen but are randomized to receive one of four doses of PEG-IFN or PEG-IFN placebo administered subcutaneously once per week until results of HIV genotyping/phenotyping are available (approximately 4 weeks). Patients who respond with a 0.5 log or greater decrease in HIV RNA at Week 4 have optimized HAART added to their ongoing PEG-IFN regimen and are followed for 24 weeks in an observational study.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

  • Have HIV levels of more than 2000 copies/ml.
  • Have failed their current HAART (had a significant increase in their HIV levels with HAART).
  • Have a CD4 cell count greater than 200 cells/microL.
  • Have had more than 6 months of HAART.
  • Have been on their current HAART for at least 6 weeks.
  • Agree to use an effective method of birth control during the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have a history of a serious mental disorder.
  • Are allergic to interferons.
  • Are pregnant or breast-feeding.
  • Are taking certain medications such as ribavirin, hydroxyurea, and ganciclovir.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005012

  Show 22 Study Locations
Sponsors and Collaborators
Schering-Plough
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00005012     History of Changes
Other Study ID Numbers: B010, P00737
Study First Received: March 29, 2000
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Interferon Alfa-2b
Lymphocyte Transformation
CD4 Lymphocyte Count
RNA, Viral
Virus Inhibitors
Anti-HIV Agents
Viral Load

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Peginterferon alfa-2b
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 16, 2014